Google goes cancer: Researchers use search engine algorithm to find cancer biomarkers

May 17, 2012

The strategy used by Google to decide which pages are relevant for a search query can also be used to determine which proteins in a patient's cancer are relevant for the disease progression. Researchers from Dresden University of Technology, Germany, have used a modified version of Google's PageRank algorithm to rank about 20,000 proteins by their genetic relevance to the progression of pancreatic cancer. In their study, published in PLoS Computational Biology, they found seven proteins that can help to assess how aggressive a patient's tumor is and guide the clinician to decide if that patient should receive chemotherapy or not.

The researcher's own version of the algorithm has been used in this study to find new , which are molecules produced by . Biomarkers can help to detect cancer earlier in body fluids or directly in the obtained in an operation or biopsy. Finding these biomarkers is often difficult and time consuming. Another problem is that markers found in different studies for the same almost never overlap.

This problem has been circumvented using the Google strategy, which takes into account the content of a web page and also how these pages are connected via hyperlinks. With this strategy as the model, the authors made use of the fact that proteins in a cell are connected through a network of physical and regulatory interactions; the 'protein Facebook' so to speak.

"Once we added the network information in our analysis, our biomarkers became more reproducible," said Christof Winter, the paper's first author. Using this network information and the Google Algorithm, a significant overlap was found with an earlier study from the University of North Carolina. There, a connection was made with a protein which can assess aggressiveness in pancreatic cancer.

Although the new biomarkers seem to mark an improvement over currently used diagnostic tools, they are far from perfect and still need to be validated in a larger follow-up study before they can be used in clinical practice. It remains an open problem to turn these insights into novel drugs which slow down cancer progression. A first step in this direction is the group's cooperation with the Dresden-based biotech company RESprotect, who are running a clinical trial on a pancreas cancer drug.

TU Dresden is a leading German university, whose Center for Regenerative Therapies was awarded excellence status in the national excellence initiative. The work was a cooperation between the bioinformatics group of Prof. Dr. Michael Schroeder and the medical groups of Dr. Christian Pilarsky and Prof. Robert Grützmann.

Explore further: Biomarker family found for chemo resistant breast cancers

More information: Winter C, Kristiansen G, Kersting S, Roy J, Aust D, et al. (2012) Google Goes Cancer: Improving Outcome Prediction for Cancer Patients by Network-Based Ranking of Marker Genes. PLoS Comput Biol 8(5): e1002511. doi:10.1371/journal.pcbi.1002511

Related Stories

Biomarker family found for chemo resistant breast cancers

April 12, 2012
Biomarkers which could help to predict resistance to chemotherapy in breast cancer patients have been identified by researchers from the University of Hull, UK.

New prostate cancer biomarkers move closer to clinical use

June 17, 2011
Conway Fellow, Professor William Watson and Professor John Fitzpatrick, UCD School of Medicine and Medical Science and Mater Misericordiae University Hospital recently received a translational research award for the validation ...

Singling out the real breast cancer among the lumps

October 25, 2011
(Medical Xpress) -- Early detection of breast cancer saves thousands of lives each year. But screening for breast cancer also produces false alarms, which can cause undue stress and costly medical bills. Now, a recent study ...

Recommended for you

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

New study points the way to therapy for rare cancer that targets the young

November 21, 2017
After years of rigorous research, a team of scientists has identified the genetic engine that drives a rare form of liver cancer. The findings offer prime targets for drugs to treat the usually lethal disease, fibrolamellar ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.